An analysis of FDA side-effects reports by healthcare informatics firm AdverseEvents has uncovered potentially worrisome signals for two of Novartis’ meds, Exelon for Parkinson’s and Alzheimer’s disease, and Stalevo for Parkinson’s disease. AdverseEvents reported 11 cases of cardiopulmonary failure, 5 cases of acute respiratory failure and almost 1,200 deaths in Exelon patients. The research also linked Stalevo to 8 cases of stroke. Via FiercePharma. Posted April 7, 2015.
Alzheimer’s disease is scary. While pharmaceutical treatments exist, their effectiveness is minimal at best, and…
